Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2) [Added supplements: COVID-19 Variant Supplement; sex as a biological variable supplement]
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 170344, 171482, 175560
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$834,500Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
PendingResearch Location
CanadaLead Research Institution
Keenan Research Centre (Toronto, ON)Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
UnspecifiedNot Applicable
Vulnerable Population
UnspecifiedNot applicable
Occupations of Interest
UnspecifiedNot applicable
Abstract
An epidemic caused by a novel coronavirus (SARS-CoV-2) has spread rapidly in China and 27 other countries. As of 15 February 2020, over 69,000 cases of COVID-19 have been reported, with 1,666 deaths. The enormous health, economic and social impact clearly make it paramount to better understand the pathogenesis of COVID-19, as no specific drugs are available to combat COVID-19. To address this issue we have put together a world-class international research team of basic scientists and clinicians who have a track record of working together and have access to resources [SARS-CoV-2, cell and animal models, a candidate drug, biotech company, and patients (in China)]. This research proposal focuses on the role of angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor to enter human body. We propose to do basic studies to examine the specific mechanisms involved, as well as to perform a clinical trial in COVID-19 patients in China using recombinant human ACE2 (rhACE2).